Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
6
×
life sciences
national blog main
national top stories
new york top stories
6
×
san francisco top stories
zolgensma
6
×
boston blog main
boston top stories
clinical trials
gene therapy
national
new york blog main
novartis
san diego blog main
san diego top stories
san francisco blog main
biogen
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
fda
indiana blog main
indiana top stories
raleigh-durham blog main
raleigh-durham top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
glaxosmithkline
spinal muscular atrophy
startups
abbvie
amgen
avexis
brian kaspar
What
roundup
bio
news
biotech
drug
fda
medicine
nash
new
remains
therapy
according
akcea
america
approval
approved
atrophy
august
biogen
biogen’s
biopharmaceutical
busy
cases
centers
cigarettes
companies
continues
control
convo
convoluted
crude
cutting
daily
days
deaths
decisions
democrats
despite
devices
disease
Language
unset
Current search:
zolgensma
×
biotech
×
" new york top stories "
×
@xconomy.com
3 years ago
FDA Green-Lights Roche Spinal Muscular Atrophy Drug, First Oral Therapy
@xconomy.com
4 years ago
Biotech Roundup: Vaping Toll Rises, NASH News, Akcea Shakeup & More
@xconomy.com
4 years ago
Bio Roundup: Sarepta’s Stumble, Opioid Suits, Shkreli’s Legacy & More
@xconomy.com
4 years ago
Encoded Nabs $104M, Illumina’s Help, to Push Gene Therapy’s Limits
@xconomy.com
5 years ago
Bio Roundup: Head and Spine Previews, Biogen Moves, IPO Dreams & More
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More